Enter inventor name

Alvin Jerald Glasky

This inventor holds 20 USPTO granted patents and 3 EPO patents. Top assignees: Neotherapeutics, Inc., Spectrum Pharmaceuticals, Inc., Merck Eprova Ag. Active years: 1992-2014.

USPTO Granted Patents = 20

% Patents Active = 80.0

EPO Patents = 3

Average Co-Inventor Count = 1.9

ph-index = 9

Forward Citations = 208(Granted Patents)

Location History:

Santa Ana, CA (US) (1992)
Tustin, CA (US) (1995 - 2005)
Mission Viejo, CA (US) (2004 - 2014)

Company Filing History:

7 out of 7

Neotherapeutics, Inc.

patents

6 out of 38

Spectrum Pharmaceuticals, Inc.

Sprectrum Pharmaceuticals, Inc.

patent

5. 5 out of 834,411

Other

patents

Years Active: 1992-2014

Loading Chart...

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8734818 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives (2014-05-27),

2. 8377456 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives (2013-02-19),

3. 8063233 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives (2011-11-22),

4. 7531670 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives (2009-05-12),

5. 6982269 - Methods for treating cognitive/attention deficit disorders using tetrahydroindolone analogues and derivatives (2006-01-03),

6. 6849735 - Methods of synthesis for 9-substituted hypoxanthine derivatives (2005-02-01),

7. 6770638 - Tetrahydroindolone and purine derivatives linked to arylpiperazines (2004-08-03),

8. 6759427 - Synthesis and methods of use of tetrahydroindolone analogues and derivatives (2004-07-06),

9. 6630490 - Methods for treatment of disease-induced peripheral neuropathy and related conditions (2003-10-07),

10. 6630478 - Methods for treatment of drug-induced peripheral neuropathy (2003-10-07),

11. 6407237 - Crystal forms of 9-substituted hypoxanthine derivatives (2002-06-18),

12. 6350752 - Carbon monoxide dependent guanylyl cyclase modifiers and methods of use (2002-02-26),

13. 6338963 - Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis (2002-01-15),

14. 6303617 - Serotonin-like 9-substituted hypoxanthine and methods of use (2001-10-16),

15. 6297226 - Synthesis and methods of use of 9-substituted guanine derivatives (2001-10-02),

Title: The Innovative Mind of Alvin Jerald Glasky

Introduction

Alvin Jerald Glasky, a prolific inventor based in Tustin, California, has made significant contributions to the field of treating cognitive and attention deficit disorders. With a remarkable portfolio of 20 patents, Glasky's innovations have paved the way for new treatments that leverage the potential of tetrahydroindolone derivatives.

Latest Patents

Among his latest patents, Glasky has developed methods for treating cognitive and attention deficit disorders using tetrahydroindolone analogues and derivatives. These patents outline the unique therapeutic potential of these compounds, showcasing methodologies that utilize these derivatives effectively in clinical settings. The advancements proposed in these patents hold promise for enhancing treatment options for individuals affected by such disorders.

Career Highlights

Glasky's career has seen him engaged with notable companies, including Neotherapeutics, Inc. and Spectrum Pharmaceuticals, Inc. His work within these organizations has allowed him to advance his research and implement innovative solutions in pharmaceuticals, specifically targeting mental health challenges.

Collaborations

Throughout his career, Glasky has collaborated with distinguished colleagues, including David B. Fick and David R. Helton. These partnerships have contributed significantly to the momentum of his research endeavors and the successful development of his patented innovations.

Conclusion

Alvin Jerald Glasky stands out as a visionary inventor whose work is shaping the future of treatments for cognitive and attention deficit disorders. With a wealth of patents that underscore his dedication to medical innovation, Glasky continues to influence the landscape of mental health treatment through his pioneering contributions.

Profile summary based on public USPTO records.

Please report any incorrect information to [email protected]